Evidence map›Paper›PMID 41403895›Full record

ArticleCancer pathogenesis and therapy2026

Neuroendocrine prostate cancer (NEPC)-associated

Zhuocheng Lai, Chenxi Hu, Jirong Jie, Yongyuan Xiao, Yuanchao Zhu, Xueni Guo, Yintong Liu, Yiwei Wang, Shiyu Pang, Xiangbo Zeng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer pathogenesis and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhuocheng LaiDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Chenxi HuDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Jirong JieDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Yongyuan XiaoDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Yuanchao ZhuDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Xueni GuoSchool of Medicine, Southern Medical University, Guangzhou, Guangdong 510515, China.
Yintong LiuSchool of Medicine, Southern Medical University, Guangzhou, Guangdong 510515, China.
Yiwei WangSchool of Medicine, Jinan University, Guangzhou, Guangdong 510632, China.
Shiyu PangDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Xiangbo ZengDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Wanlong TanDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Qiong WangDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of castration-resistant prostate cancer (CRPC) that is typically resistant to nearly all current therapies. In this study, single-cell RNA sequencing (scRNA-seq) and dataset analyses identified Centrosomal Protein 55 (

Indexed as

Castration-resistant prostate cancerCEP55Cisplatin resistanceNeuroendocrine prostate cancerProstate cancer

Identifiers

PMID41403895
PMCPMC12704070

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.